Product Profiles - Ophthalmology Times Europe

ADVERTISEMENT

CATARACT

GLAUCOMA

REFRACTIVE

RETINA

Tweet!
Product Profiles

Ophthalmology Times Europe
Volume 8, Issue 2

Preservative-free glaucoma eye drops

Taflotan, developed by Santen, is a preservative-free prostglandin eye drop tailored for glaucoma patients. The drops provide an alternative treatment for lowering intraocular pressure.

The eye drops are an ideal solution for patients who experience side effects from glaucoma eye drops with preservatives. Taflotan is also well-suited for dry and sensitive eyes.



Results from several recent studies have demonstrated the safety and efficacy of Taflotan. The eye drops reduce ocular symptoms and signs.

For further information please visit http://www.santen.com/

Visual field data analysis tool

Oculus have released the Glaucoma Staging Program (GSP)- the latest software enhancement for use with the Oculus Easyfield, Centerfield 2 and Twinfield 2 perimeters.

GSP can be installed as an upgrade for any visual data analysis tools that may already be in use. It is able to detect subtle visual field changes linked to the early stages of glaucoma.

The tool performs a multi-level classification of clinical findings into either 'Normal', 'Glaucomatous', 'Artifactual' and 'Neuro'.



This corresponds to different glaucoma severity levels. Results are displayed in the form of colour-coded bar charts. The charts present the confidence level of glaucoma severity classification.

For further information visit http://www.oculus.de


On a scale of 1 to 10, with 1 being the lowest and 10 being the highest, how would you rate this article?
Your original vote has been tallied and is included in the ratings results.
View our top pages
Average rating for this page is: 2.5
WHAT DO YOU THINK?

AddThis Social Bookmark Button

Rate this article
Your comments
Discuss on our forum
Follow us on Twitter

 

Survey
What do you believe is the most appropriate glaucoma therapy option?
Monotherapy
Multiple therapies
Fixed-dose combinations
Various/individualized treatment
Monotherapy
25%
Multiple therapies
0%
Fixed-dose combinations
13%
Various/individualized treatment
63%
View Results
Source: Ophthalmology Times Europe,
Click here